This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.00% per year. These returns cover a period from January 1, 1988 through May 4, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Abbott's (ABT) Q4 Earnings Match Estimates, Margins Rise
by Zacks Equity Research
Abbott (ABT) delivers better-than-expected revenues and in-line earnings for the fourth quarter of 2023.
Will the Individual MA Unit Aid Humana's (HUM) Q4 Earnings?
by Zacks Equity Research
Humana's (HUM) Q4 results are likely to gain from growing premiums and an expanding customer base within its individual Medicare Advantage and Medicaid units, partly offset by higher marketing spend.
Compared to Estimates, Surgery Partners (SGRY) Q3 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Surgery Partners (SGRY) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Surgery Partners (SGRY) Soars 9.9%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Surgery Partners (SGRY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Surgery Partners (SGRY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Surgery Partners (SGRY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ensign Group (ENSG) Pursues Facility Buyouts in South Carolina
by Zacks Equity Research
Ensign Group (ENSG) acquires two skilled nursing facilities in South Carolina to offer enhanced healthcare services to the state's residents.
Select Medical (SEM) Up 18% Year to Date: More Room to Run?
by Zacks Equity Research
Select Medical (SEM) is well-poised for growth on the back of a credible healthcare facility portfolio built through buyouts and JVs coupled with strong cash-generating abilities.
Zacks Industry Outlook Highlights Medpace, HealthEquity and Surgery Partners
by Zacks Equity Research
Medpace, HealthEquity and Surgery Partners are part of the Zacks Industry Outlook article.
3 Medical Services Stocks Countering Industry-Wide Headwinds
by Urmimala Biswas
The Zacks Medical - Services industry is growing on digital healthcare adoption. MEDP, HQY and SGRY are set to gain the most. However, staffing shortages may disrupt the trend.
Down -22.17% in 4 Weeks, Here's Why Surgery Partners (SGRY) Looks Ripe for a Turnaround
by Zacks Equity Research
Surgery Partners (SGRY) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.